title: Novel glutamatergic agents for major depressive disorder and bipolar disorder.
abstract: Mood disorders such as major depressive disorder (MDD) and bipolar disorder (BPD) are common, chronic, recurrent mental illnesses that affect the lives and functioning of millions of individuals worldwide. Growing evidence suggests that the glutamatergic system is central to the neurobiology and treatment of these disorders. Here, we review data supporting the involvement of the glutamatergic system in the pathophysiology of mood disorders as well as the efficacy of glutamatergic agents as novel therapeutics.
authors.affiliation: LIM-27, Institute and Department of Psychiatry, University of Sao Paulo Medical School, USP, Sao Paulo, Brazil.
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Machado-Vieira
authors.forename: Lobna
authors.initials: L
authors.lastname: Ibrahim
authors.forename: Ioline D
authors.initials: ID
authors.lastname: Henter
authors.forename: Carlos A
authors.initials: CA
authors.lastname: Zarate
mesh_terms: D001714:Bipolar Disorder / Q000188:drug therapy*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D017470:Receptors, Glutamate / Q000187:drug effects*
chemical_list: D017470:Receptors, Glutamate